EGFR and sarcoma: To determine the biological effect of BUB1 in sarcomas, we performed a pharmacologic inhibition of the activity of this kinase using the inhibitor 2-OH-BNPP1, which was previously described to preclude the kinase activity of BUB1 and block the EGFR and TGF-β signaling pathways [31,32].